Intracorporeal vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03469362|
Recruitment Status : Recruiting
First Posted : March 19, 2018
Last Update Posted : March 1, 2021
|Condition or disease||Intervention/treatment||Phase|
|Bladder Cancer||Procedure: Extracorporeal Urinary Diversion Procedure: Intracorporal Urinary Diversion Device: Da Vinci Robot||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||88 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized Clinical Trial of Intracorporeal vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy|
|Actual Study Start Date :||April 25, 2018|
|Estimated Primary Completion Date :||June 2023|
|Estimated Study Completion Date :||June 2026|
Experimental: Extracorporeal Urinary Diversion (ECD)
Participants will be randomized to receiving ECD after scheduled Robotic Assisted Radical Cystectomy (RARC).
Procedure: Extracorporeal Urinary Diversion
Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
Other Name: ECD
Experimental: Intracorporal Urinary Diversion (ICD)
Participants will be randomized to receiving ICD after scheduled Robotic Assisted Radical Cystectomy (RARC).
Procedure: Intracorporal Urinary Diversion
Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.
Other Name: ICD
Device: Da Vinci Robot
Da Vinci Robotic Surgical System
- 90-day Major Post-Operative Complication Rate [ Time Frame: 90 days ]Major complication rate at 90-days from RARC + urinary diversion using the modified Clavien-Dindo grading system. Major complication is defined as Clavien-Dindo Grade ≥ 3.
- 90-day Any Post-Operative Complication Rate [ Time Frame: 90 days ]Any complication rates at 90-days from RARC + urinary diversion, using the modified Clavien-Dindo grading system as low grade (1-2) or high grade (3-5).
- Length of Hospital Stay in ECD vs ICD Study Participants [ Time Frame: About 2 weeks ]Length of hospital stay for study participants undergoing ECD versus ICD urinary diversion post-RARC, as recorded at hospital discharge.
- 90-day Readmission Rate [ Time Frame: 90 days ]Rate of readmission to hospital at 90 days post-RARC followed by ECD or ICD urinary diversion.
- Rate of Return to the Operating room within 90 days [ Time Frame: Up to 90 days ]Rate of return to the operating room within 90 days after RARC followed by ICD or ECD Urinary Diversion.
- Mortality Rate at 90 days [ Time Frame: 90 days ]Rate of mortality (death) at 90 days in study participants
- Rate of Bowel-Specific Complications [ Time Frame: Up to 36 months ]Rate of bowel-specific complications in study participants (including incidence of mechanical bowel obstruction, anastomotic leaks, and surgical site infections) and post operative pain. Bowel-specific complications will be assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.
- Functional Independence Recovery as measured by the ADL Questionnaire [ Time Frame: Up to 36 months ]Rate of functional independence recovery as measured by patient-reported scores on the Activities of Daily Living (ADL) questionnaire. For the ADL, the total score ranges from 0 to 6, with the higher scores indicating functional improvement and lower scores indicating functional deterioration.
- Functional Independence Recovery as measured by the IADL Questionnaire [ Time Frame: Up to 36 months ]Rate of functional independence recovery as measured by an aggregate of patient-reported scores on the Instrumental Activities of Daily Living (IADL) questionnaire. For the IADL, the total score ranges from 0 to 8, with higher scores indicating functional functional improvement and lower scores indicating functional deterioration.
- Functional Independence Recovery as measured by the Hand Grip Strength Test. [ Time Frame: Up to 36 months ]The Hand Grip Strength Test measures the amount of static force that a participant's hand can squeeze around a dynamometer. The test is measured in kilograms.
- Functional Independence Recovery as measured by the Timed Up and Go (TUG) Walking Test [ Time Frame: Up to 36 months ]The TUG test times participants as they rise from a standard chair, walk 3 meters, turn, walk back and sit again. The test is measured in seconds.
- Health-Related Quality of Life (HRQoL) as assessed by SF-8 Health Survey [ Time Frame: Up to 36 months ]HRQoL measured by patient scores on the Short Form 8 (SF-8) Health Survey. The SF-8 is a questionnaire consisting of 8-items and two component summary scores: Physical component summary (PCS) and mental component summary (MCS). They are scored by weighting each score to a norm-based scoring model. The total scores will be reported as a percentile with higher score indicating better health-related quality of life.
- HRQoL as assessed by the FACT-VCI Questionnaire [ Time Frame: Up to 36 months ]HRQoL measured by patient scores on the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) questionnaire. The FACT-VCI is a condition-specific instrument for patients undergoing radical cystectomy (RC) and urinary diversion (UD) for bladder cancer. The questionnaire consists of 44 items scored on a range from 0 ("Not at all") to 4 ("Very Much"), resulting in an ordinal Likert scale, with higher scores indicating a better HRQoL. The FACT-VCI measures quality of life across five domains: Physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and an additional concerns subscale.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03469362
|Contact: Rody Barakatemail@example.com|
|United States, Florida|
|Miami, Florida, United States, 33136|
|Contact: Rody L Barakat 305-243-2177 firstname.lastname@example.org|
|Principal Investigator: Mark L Gonzalgo, MD, PhD|
|Principal Investigator:||Mark L Gonzalgo, MD, PhD||University of Miami|